BCR and acute lymphoblastic leukemia: Targeted therapy of BCR-ABL + ALL with ABL-specific tyrosine kinase inhibitors (TKI) such as imatinib and dasatinib combined with induction and post-remission chemotherapy prolongs remission but relapse rates remain high [4].